Top

Clinical Drug Investigation

Published in:

01-08-2010 | Original Research Article

Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK

A Chronic Kidney Disease Markov Model

Authors: Dr Mark Nuijten, Dennis L. Andress, Steven E. Marx, Alistair S. Curry, Raimund Sterz

Published in: Clinical Drug Investigation | Issue 8/2010

Abstract

Background: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) and a frequent cause of clinically significant bone disease. Non-selective vitamin D receptor (VDR) activator treatment has been used to treat the condition but is ineffective for many patients with hypercalcaemia and hyperphosphataemia and may precipitate worsening of their condition. Compared with non-selective VDR activator treatment, use of the VDR ligand paricalcitol may increase survival and reduce the risk of morbidities in patients with SHPT, which may have health economic consequences.

Objective: The objective of this study was to determine the cost effectiveness of paricalcitol versus a non-selective VDR activator for the treatment of SHPT in patients with CKD in the UK setting.

Methods: A Markov process model was developed employing data sources from the published literature, paricalcitol clinical trials and observational studies, official UK price/tariff lists and national population statistics. The comparator was alfacalcidol, a non-selective VDR activator medication. The primary perspective of the study was that of the UK National Health Service (NHS). The efficacy outcomes (reductions in SHPT, proteinuria, complications and mortality) were extrapolated to: number of life-years gained (LYG) and number of quality-adjusted life-years (QALYs). Clinical and economic outcomes were discounted at 3.5%. The year of costing for costs determined in the study was 2006.

Results: The reference case analysis was a 10-year time horizon, based on a comparison of paricalcitol with a non-selective VDR activator, which is started in CKD stage 3 (moderate reduction in glomerular filtration rate [GFR] with kidney damage) and continued in CKD stage 4 (severe reduction in GFR) and CKD stage 5 (established kidney failure). The use of paricalcitol leads to an additional medical cost of £3224 ($US5970). The health benefits of paricalcitol lead to an increase in LYG of 0.52 and a gain in QALYs of 0.465. Therefore the use of paricalcitol results in an incremental cost-effectiveness ratio of £6933/QALY ($US12 840/QALY) from the primary perspective of the NHS. One-way sensitivity analyses and probabilistic sensitivity analyses confirmed the robustness of the model.

Conclusion: This model showed that the favourable clinical benefit of paricalcitol results in positive short- and long-term health economic benefits. This study suggests that the use of paricalcitol in patients with early CKD may be cost effective from the UK NHS perspective versus non-selective VDR activator medication.

Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004; 17: 209–16PubMedCrossRef

Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33–43PubMedCrossRef

Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D3 analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13–20PubMedCrossRef

Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy 1996; 16: 619–30PubMed

Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115–21PubMedCrossRef

Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000; 320: 100–6PubMedCrossRef

Tuma SN, Martin RR, Mallette LE, et al. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J Lab Clin Med 1981; 97: 291–8PubMed

Chervu I, Kiersztein M, Alexiewicz JM, et al. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. Kidney Int 1992; 41: 1501–5PubMedCrossRef

Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606–20PubMedCrossRef

10.

Huraib S, Tanimu D, Romeh SA, et al. Effects of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis 1998; 32: 1036–40PubMedCrossRef

11.

Rubinger D, Friedlander MM, Silver J, et al. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: a possible role of iron overload. Am J Kidney Dis 1986; VII: 125–9

12.

Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19Suppl. 5: V2–8PubMedCrossRef

13.

Warnock DG. Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease. Kidney Int 2004; 92 Suppl.: S121–3CrossRef

14.

Llach F, Velasquez-Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38 Suppl. 5: S20–33CrossRef

15.

National Kidney Foundation KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [online]. Available from URL: http://www.kidney.org/professionals/KDOQI/guidelines_ ckd/p4_class_g1.htm [Accessed 2010 May 11]

16.

Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kid Dis 1995; 26: 852–60PubMedCrossRef

17.

Finch J, Brown A, Slatolpolsky E. Differential effects of 1,25-dihydroxy-vitamin D₃ and 19-nor-1,25-dihydroxy-vitamin D₂ on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999}; 10}: 980–5PubMed

18.

Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283–8PubMedCrossRef

19.

Martin KJ, Gonzales EA, Gellens M, et al. 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427–32PubMed

20.

Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315–23PubMed

21.

Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483–90PubMedCrossRef

22.

Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38Suppl. 5: S45–50PubMedCrossRef

23.

Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–8PubMedCrossRef

24.

Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol Therapy. N Engl J Med 2003; 349: 446–56PubMedCrossRef

25.

Dobrez D, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical setting. Nephrol Dial Transplant 2004; 5: 1174–81CrossRef

26.

Nuijten MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998; 4: 433–55CrossRef

27.

Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices — modeling studies. Value Health 2003; 6: 9–17PubMedCrossRef

28.

Barr J, Schumacher GE. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 1197–214

29.

Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38PubMedCrossRef

30.

Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–100PubMedCrossRef

31.

NICE Technology Appraisals No. 5, 2001 guidance for manufacturers and sponsors [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 May 1]

32.

Roze S, Valentine J, Zakrzewska KE, et al. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabetic Med 2005; 24: 1239–45CrossRef

33.

Palmer AJ, Rodby RA. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int 2004; 92 Suppl.: S118–20CrossRef

34.

Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 Jun; 9(22): 1–160PubMed

35.

Roderick P, Nicholson T, Armitage A, et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess 2005; 9: 1–178

36.

Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular disease in the United Kingdom. Heart 2006; 92: 1384–9PubMedCrossRef

37.

Personal Social Services Research Unit. Unit costs of health and social care 2003 [online]. Available from URL: http://www.pssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf [Accessed 2007 Apr 30]

38.

Keith D, Nicholas G, Gullion C, et al. Mortality of chronic kidney disease in a large HMO population [abstract]. J Am Soc Nephrol 2002; 13: 620A

39.

Nuijten M, Andress L, Marx S, et al. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009; 25(5): 1221–34PubMedCrossRef

40.

Bakris GL, Levin A, Molitch M, et al. Disturbances of serum 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] in patients with chronic kidney disease [abstract]. J Am Soc Nephrol 2005; 16: 495A

41.

Smith D, Gullion C, Nichols G, et al. Cost of medical care for CKD and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15: 1300–6PubMedCrossRef

42.

Schumock GT, Andress DL, Marx SE, et al. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in predialysis CKD patients. Curr Med Res Opin 2008; 24(11): 3037–49PubMedCrossRef

43.

Kalantar-Zadeh K, Marx SE, Schumock G, et al. Examination of outcomes and costs of care among patients with chronic kidney disease and secondary hyperparathyroidism [abstract]. J Am Soc Nephrol 2006; 17: 647A

44.

Dinneen S, Gerstein H. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157: 1413–8PubMedCrossRef

45.

Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101–14PubMedCrossRef

46.

Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68: 2801–8PubMedCrossRef

47.

Hogan TJ, Elliott WJ, Seto AH, et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002; 20: 37–47PubMedCrossRef

48.

Smith DH, Johnson EJ, Thorp ML, et al. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab 2009; 27(3): 287–94PubMedCrossRef

49.

Nuijten MJC. Data management in modelling studies: the selection of data sources. Pharmacoeconomics 1998; 3: 305–16CrossRef

50.

Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the Treatment of Patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54(4): 647–52PubMedCrossRef

Title: Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK
A Chronic Kidney Disease Markov Model
Authors: Dr Mark Nuijten
Dennis L. Andress
Steven E. Marx
Alistair S. Curry
Raimund Sterz
Publication date: 01-08-2010
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 8/2010
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/11536310-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK

A Chronic Kidney Disease Markov Model

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2010

Proton Pump Inhibitor-Induced Neutropenia

A Cost-Consequence Analysis of Pregabalin versus Usual Care in the Symptomatic Treatment of Refractory Low Back Pain

Treating Psoriasis with Etanercept in Italian Clinical Practice

Cost of Myocardial Infarction to the Australian Community

Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee